|
|
|
Volumn 120, Issue 1260, 2007, Pages
|
|
PHARMAC responds on Herceptin assumptions and decisions.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
BREAST TUMOR;
CLINICAL TRIAL;
DRUG INDUSTRY;
ECONOMICS;
FEMALE;
HUMAN;
NEW ZEALAND;
NOTE;
PUBLIC HEALTH;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DRUG INDUSTRY;
FEMALE;
HUMANS;
NATIONAL HEALTH PROGRAMS;
NEW ZEALAND;
|
|
EID: 34548405955
PISSN: None
EISSN: 11758716
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
